유행성 각결막염은 Adenovirus 8, 19형이 주로 질환을 일으키는 안과 영역에서 가장 흔한 전염성 질환중의 하나이다. 이의 치료제로서는 아직 특효약이 있는 것은 아니나, 저자들은 유전자 재조합 기술로 생산한 고농도의 유전자 재조합 알파 인터페론 안약(Recombinant Human alpha Interferon, 30만 IU/vial, 제일제당㈜ 제품)을 가톨릭 의대 부속 강남성모병원, 한림대학 부속 강동성심병원, 중앙대학교 부속 용산병원 및 영등포 김안과 의원에서 유행성 각결막염 환자에게 점안하여 치료효과를 관찰하였으며, 또한 유행성 각결막염에 대한 감염 경로, 임상적 소견, 바이러스에 대한 in vitro 검사를 실시하였다. 대상인원은 인터페론 점안제 사용군 193명과 대조군 73명을 21일간 추적조사하여 비교 관찰후 다음과 같은 결과를 얻었다. 알려진 감염경로는 가족을 통해서가 가장 많았고 이외에 수영장, 안과의 순서였으며 유행한 바이러스는 HeLa 세포의 변형 양상에 따르면 Adenovirus감염이 가장 많았다. 인터페로 사용후 증상의 호전은 약물 투여후 평균 3.8일로 대조군의 10.8일에 비해 통계적으로 유의한 차이가 있었고, 조기 사용시 효과가 더 좋았다. 치료후 가장 좋아지는 자각정 증상은 이물감이었으며, 타각적 증상은 충혈의 소실이었다. 인터페론 사용후 특이한 부작용은 발견되지 않았으며, 사용후 통증이 8%에서 나타났다(한안지 33 : 39~48, 1992).
The one hundred ninty three patients of epidemic keratoconjunctivitis(EKC) were treated with recombinant human alpha interferon(Re-Hu-INF-a eyedrop, 30,000IU/Vial, Cheil Food & Cemicals Inc.) at kangnam St. Mary`s Hosp., Catholic University Medical College, Chungang University Hosp., Kangdong Sacred Heart Hosp., Hallym University and Kims`s Eye Clinic and the following results were obtained after at least 21 days follow-up. 1. The total patients of EKC were 266 ; 193 of patients were treated with INF and another 73 patients were treated with antibiotic eye drop only as a control group. The age ranged from 3 to 79 year-old and the average age were 29.6 in interferon group and 36.3 in control group. 2. There was no significant difference between two groups in number of eyes involved. The frequencey of infection route was family, swimming pool, and eye clinic order. Adenovirus was the most common causative agent according at the cytopathic effect of HeLa cell inoculation. 3. in most of cases, there was little symptomatic manifestation, if ever, malaise was the most common systemic symptom in both group. In INF teated group, the subjective symptom was disappeared in 70.5% of patients within 4 days. But in control group, disappearance of subjective symptom was noted in only 17.8% of patients and the results were statistically significant. 5. The eariler INF treatment, the better improvement of EKC and the sign improved first was foreign body sensation. 6. There was little side effect of INF treatment, but ocular pain was occurred in 8%. From these results, we suggest that recombinant, human alpha interferon eyedrop in EKC treatment is effective and the earlier application is more effective especially(J Korean Ophthalmol Soc 33 : 39~48, 1992).
(0)
(0)